All News
Day 4 - Top 3 from EULAR 2020
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Read Article
Day 3 - Top 5 from EULAR 2020
These were my top abstracts from Thursday, 4th of June at EULAR 2020:
Read Article
Lots of talk about best bDMARDs in RA-ILD, but what about in RA-assoc bronchiectasis?
@Yuz6Yusof found rituximab had better 'lung survival' vs TNFi (similar baseline stats)
Something to consider in these difficult-to-treat pts?
@LeedsBRC Newcastle THU0143 #EULAR2020 @RheumNow https://t.co/XpffkDNqhU
David Liew drdavidliew ( View Tweet)
#EULAR2020 Dr. V Ritschl:EULAR Task Force on Patient Adherance: 30-80% of pts do not adhere to Rx. resulting in ⬆️dz severity, pain, fatigue, depression, decreased in function, physical activity. HCPs should discuss adherance reg. & explore factors affecting adherance. @RheumNow
k dao KDAO2011 ( View Tweet)
ENbrel works in long term for the few people left on the drug at 10 yrs with SpA. Enormous dropout. If you are still on Rx for a decade you are in the minority. Drop out of TNFi in SpA mirrors RA & PsA @RheumNow @eular_org @CRASCRRheum @earlyarthritis #EULAR2020 https://t.co/dLS2fw5uRP
Janet Pope Janetbirdope ( View Tweet)
Study in Norway reveals that the majority of the women w/ SpA were not treated with TNF inhibitors before or during pregnancy. Few on TNFi were continued on tx during pregnancy. #EULAR2020 @RheumNow https://t.co/t7B6pASeWQ https://t.co/BwU6RF5Qkn
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Switching TNFi to VDZ in pts IBD-related SpA associated w/ articular exacerbation of SpA in 1 out of 4 patients within the first 5 months. New-onset MEM is also observed in up to 15% of patients with IBD treated with VDZ. #EULAR2020 @RheumNow https://t.co/ZVjZC7hvxs https://t.co/d1RT3GzB2b
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
#EULAR2020 Recc for irAEs w/ICI:
1. GC's ok, goal<10 mg/d, any csDMARD, bDMARD (TNFi/IL-6),🚫ABT xcept life-threatening myositis
2. Myositis beware bulbar signs: dysphagia, dysarthria, dysphonia: stop ICIs,⬆️GC, IVIG/PE
3. Don't test autoAbs b/f ICI Rx
https://t.co/P5jDgnjK94
k dao KDAO2011 ( View Tweet)
Don’t forget significant fibrosis with ILD has +RCT with nintedanib INBUILD study. Lots of buzz of RA ILD where MTX is OK, TNFi may have more ILD than other bDMARDs, biomatkers KL-6 @eular_org OP0038 #EULAR2020 @CRASCRRheum https://t.co/OihF3LmNYQ
Janet Pope Janetbirdope ( View Tweet)
Can we predict which RA pts will have secondary failure to TNFi in advance?
B-cell activating factor (BAFF) may play a role, and in age >54, pre-TNFi BAFF levels predict anti-drug Ab.
A potential step toward better drug survival?
La Paz, Madrid THU0170 #EULAR2020 @RheumNow https://t.co/NRQHO2cVuf
David Liew drdavidliew ( View Tweet)
#EULAR2020 OP0019 DON'T STOP TNFi in RA remission per ARCTIC-REWIND trial: RCT X 1 year n=99 multicenter gov't funded- DAS28 remission X1 year, dz X10 yrs, 2/3 pts (RF+/CCP+), no doppler signal.
Results: 63% flared who had TNFi w/drawn vs. 5% when TNFi continued @RheumNow https://t.co/SsR1vUGbOe
k dao KDAO2011 ( View Tweet)
Do certain TNFi get more affected by obesity in RA? I have colleagues convinced infliximab is better for obese pts (weight-based dosing).
It actually seems obese RA pts might do as well as other RA pts w etanercept, but not w infliximab!
@DrMiniDey OP0220 #EULAR2020 @RheumNow https://t.co/EsaLTqINpd
David Liew drdavidliew ( View Tweet)
And another one! No association of MTX with worsening of ILD in this study by Men-Vazquez et al. #EULAR2020 https://t.co/X7C6KyC29L
Richard Conway RichardPAConway ( View Tweet)
Another Italian COVID-19 dermatology report: 1,193 skin psoriasis patients on TNFi, IL17,IL23,IL12/23 & apremilast: 22 patients infected, of those 5 hospitalised, none died https://t.co/HpN908qsHd
Dr Philip Robinson philipcrobinson ( View Tweet)
#EULAR2020 ABST#OP0012 German RABBIT registry show TNFi has less risk for venothrombolic events HR 0.53 (95% CI 0.33-0.86) compared to csDMARD in RA. Age > 65 years, CRP > 5 mg/L increases risk for VTE, no differences with steroids or smoking status.
@RheumNow https://t.co/Hkv6T7pl9f
k dao KDAO2011 ( View Tweet)
Study out of Switzerland finds lower response rates to TNFi in women with nr-axSpA vs men. Poster #THU0383 #EULAR2020 @RheumNow https://t.co/uWNqwqamQM https://t.co/pgnhCaw9f6
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
This Spanish study of 255 SpA pts found that acute unilateral anterior uveitis was the most common pattern, primarily in HLA B27+. NO difference in incidence between SEC and TNFi treated pts. #EULAR2020 @RheumNow Poster #THU0388 https://t.co/OMfG8atfE4
Dr. Rachel Tate uptoTate ( View Tweet)
COAST-V and COAST-X trial results: Both TNFi experienced and naive AS pts had better work productivity compared to PBO. #EULAR2020 @RheumNow poster #THU0396
https://t.co/UPDpLqCSkG https://t.co/UTLzxxTG8K
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
10 ReA pt study out of India reviewing ETN-b found that all pts (previously on ETN) responded to biosimilar med without new safety signals. Further details are here on abstract #AB0632 https://t.co/lRA2IDvU4H #EULAR2020 @RheumNow https://t.co/QyhwBzBBH3
Links:
Dr. Rachel Tate uptoTate ( View Tweet)
Interesting observation: obese patients seem to respond better to etanercept than to mAb TNFi @RheumNow https://t.co/WrjwE4jUNI
k dao KDAO2011 ( View Tweet)
